Skip to content

Therapeutic Option of Herbal Medicine Honeysuckle for Novel Coronavirus Pneumonia (COVID-19) : a medical records based study

Therapeutic Option of Herbal Medicine Honeysuckle for Novel Coronavirus Pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100004726
Enrollment
Unknown
Registered
2021-02-16
Start date
2020-02-06
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Western medicine diagnosis: meets the COVID-19 diagnosis criteria for confirmed patients, and Chinese medicine diagnosis: meets the New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Seventh Edition) Epidemic diagnosis criteria; 2. 18 to 75 years old, meet the common diagnostic criteria of COVID -19 Inpatients; 3. With cough symptoms.

Exclusion criteria

Exclusion criteria: 1) Primary immunodeficiency, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, lung dysplasia and other basic diseases, with clear evidence of bacterial infection; 2) Having the following conditions Subjects: Asthma requiring daily treatment, any other chronic respiratory diseases and bacterial infections of the respiratory system such as purulent tonsillitis, acute bronchitis, sinusitis, otitis media, etc., other respiratory diseases affecting clinical trial evaluation, chest CT Confirmed that there are basic lung diseases such as severe pulmonary interstitial lesions and bronchiectasis; 3) According to the diagnostic criteria of the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Seventh Edition)" [3] Diagnosed as severe and critical COVID-19; 4) Pregnant or breastfeeding women; 5) May be transferred to non-COVID-19 designated hospitals within 72 hours; 6) Allergies, such as a history of allergies to 2 or more drugs or food, or known allergies to the ingredients of this drug; 7) The investigator believes that there are any factors that are not suitable for inclusion in the group or that affect the evaluation of the curative effect of the subjects.

Design outcomes

Primary

MeasureTime frame
SARS-CoV-2-qRT-PCR;CT Imaging;

Countries

China

Contacts

Public ContactLi, Weidong

Beijing University of Chinese Medicine

viticulture@hotmail.com+86 13681420709

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026